These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25216334)

  • 21. Discovery of Small Molecules that Target Vascular Endothelial Growth Factor Receptor-2 Signalling Pathway Employing Molecular Modelling Studies.
    Rampogu S; Baek A; Park C; Parate S; Parameswaran S; Park Y; Shaik B; Kim JH; Park SJ; Lee KW
    Cells; 2019 Mar; 8(3):. PubMed ID: 30901950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies.
    Moradi M; Mousavi A; Emamgholipour Z; Giovannini J; Moghimi S; Peytam F; Honarmand A; Bach S; Foroumadi A
    Eur J Med Chem; 2023 Nov; 259():115626. PubMed ID: 37453330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative structure activity relationship and molecular simulations for the exploration of natural potent VEGFR-2 inhibitors: an
    Sharma N; Sharma M; Rahman QI; Akhtar S; Muddassir M
    J Biomol Struct Dyn; 2021 May; 39(8):2806-2823. PubMed ID: 32363995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold.
    Wang DP; Liu KL; Li XY; Lu GQ; Xue WH; Qian XH; Mohamed O K; Meng FH
    Eur J Med Chem; 2021 Feb; 211():113083. PubMed ID: 33340911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol.
    Pan X; Liang L; Si R; Wang J; Zhang Q; Zhou H; Zhang L; Zhang J
    Eur J Med Chem; 2019 Feb; 163():1-9. PubMed ID: 30503935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
    Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
    Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.
    Wang N; Wang ZY; Mo SL; Loo TY; Wang DM; Luo HB; Yang DP; Chen YL; Shen JG; Chen JP
    Breast Cancer Res Treat; 2012 Aug; 134(3):943-55. PubMed ID: 22350787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
    Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
    Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation.
    Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
    Al-Hussain SA; Farghaly TA; Zaki MEA; Abdulwahab HG; Al-Qurashi NT; Muhammad ZA
    Bioorg Chem; 2020 Dec; 105():104330. PubMed ID: 33038552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.
    Lu L; Saha D; Martuza RL; Rabkin SD; Wakimoto H
    J Neurooncol; 2015 Jan; 121(1):91-100. PubMed ID: 25213669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.
    Ku X; Heinzlmeir S; Helm D; Médard G; Kuster B
    J Proteome Res; 2014 May; 13(5):2445-52. PubMed ID: 24712744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.
    Rössler J; Monnet Y; Farace F; Opolon P; Daudigeos-Dubus E; Bourredjem A; Vassal G; Geoerger B
    Int J Cancer; 2011 Jun; 128(11):2748-58. PubMed ID: 20715103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular simulation studies to reveal the binding mechanisms of shikonin derivatives inhibiting VEGFR-2 kinase.
    Munni YA; Ali MC; Selsi NJ; Sultana M; Hossen M; Bipasha TH; Rahman M; Uddin MN; Hosen SMZ; Dash R
    Comput Biol Chem; 2021 Feb; 90():107414. PubMed ID: 33191109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding.
    Kendrew J; Eberlein C; Hedberg B; McDaid K; Smith NR; Weir HM; Wedge SR; Blakey DC; Foltz I; Zhou J; Kang JS; Barry ST
    Mol Cancer Ther; 2011 May; 10(5):770-83. PubMed ID: 21388971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway.
    Tang N; Shi L; Yu Z; Dong P; Wang C; Huo X; Zhang B; Huang S; Deng S; Liu K; Ma T; Wang X; Wu L; Ma XC
    Oncotarget; 2016 Jan; 7(3):3533-47. PubMed ID: 26657289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Angiogenic Property of Free Human Oligosaccharides.
    Bae B; Kim H; Park H; Koh YJ; Bae SJ; Ha KT
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34064180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of novel pyridazinoquinazoline derivatives as potent VEGFR-2 inhibitors: In vitro and in vivo study.
    El-Gazzar MG; El-Hazek RM; Zaher NH; El-Ghazaly MA
    Bioorg Chem; 2019 Nov; 92():103251. PubMed ID: 31525526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
    Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F
    Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.